FOXP3 and neoplasm: Based on our findings, a significant decrease in the frequency of CD25+ Foxp3+ Treg cells in the spleen and tumor site denoted that the current combination restricted the pre-existed tumor-supportive immunity with the significantly lower secretion of IL-10 in this group than single treated and non-liposomal peptide plus CpG-ODN groups.